Breaking News Instant updates and real-time market news.

ABBV

AbbVie

$82.96

-1.31 (-1.55%)

, ALXN

Alexion

$122.99

-0.92 (-0.74%)

04:55
10/24/18
10/24
04:55
10/24/18
04:55

The ACR and ARHP to hold annual meeting

American College of Rheumatology & Association of Rheumatology Professionals will hold the 2018 ACR/ARHP Annual Meeting in Chicago on October 19-24.

ABBV

AbbVie

$82.96

-1.31 (-1.55%)

ALXN

Alexion

$122.99

-0.92 (-0.74%)

AMGN

Amgen

$197.54

-0.5 (-0.25%)

AUPH

Aurinia Pharmaceuticals

$5.29

-0.14 (-2.58%)

BMY

Bristol-Myers

$50.63

-0.24 (-0.47%)

CELG

Celgene

$79.75

-0.84 (-1.04%)

DGX

Quest Diagnostics

$95.19

-6.34 (-6.24%)

DNA

Bought by RHHBY

$0.00

(0.00%)

FLXN

Flexion

$16.66

-0.57 (-3.31%)

GILD

Gilead

$71.64

-0.71 (-0.98%)

GSK

GlaxoSmithKline

$40.63

0.12 (0.30%)

REGN

Regeneron

$380.37

-7.79 (-2.01%)

RARE

Ultragenyx

$61.53

-0.56 (-0.90%)

QDEL

Quidel

$65.16

0.75 (1.16%)

PFE

Pfizer

$44.09

-0.28 (-0.63%)

NVS

Novartis

$88.01

0.89 (1.02%)

MRK

Merck

$72.09

-0.47 (-0.65%)

MCK

McKesson

$127.25

0.54 (0.43%)

LLY

Eli Lilly

$110.41

-1.66 (-1.48%)

TMO

Thermo Fisher

$223.46

-2.29 (-1.01%)

TKPYY

Takeda Pharmaceutical

$0.00

(0.00%)

SELB

Selecta Biosciences

$8.91

-4.46 (-33.36%)

  • 24

    Oct

  • 24

    Oct

  • 25

    Oct

  • 25

    Oct

  • 25

    Oct

  • 25

    Oct

  • 25

    Oct

  • 28

    Oct

  • 29

    Oct

  • 30

    Oct

  • 30

    Oct

  • 31

    Oct

  • 02

    Nov

  • 06

    Nov

  • 06

    Nov

  • 06

    Nov

  • 07

    Nov

  • 09

    Nov

  • 12

    Nov

  • 13

    Nov

  • 27

    Nov

  • 11

    Jan

  • 16

    Feb

  • 18

    Feb

  • 28

    Apr

  • 13

    May

  • 20

    May

ABBV AbbVie
$82.96

-1.31 (-1.55%)

10/23/18
WOLF
10/23/18
INITIATION
Target $85
WOLF
Underperform
AbbVie initiated with an Underperform at Wolfe Research
Wolfe Research analyst Time Anderson reinitiated AbbVie with an Underperform and $85 price target.
10/22/18
RHCO
10/22/18
NO CHANGE
Target $135
RHCO
Buy
AbbVie price target lowered to $135 from $157 at SunTrust
SunTrust analyst John Boris lowered his price target on AbbVie to $135 after his discussions with its management about the challenges coming from "Humira biosimilar discounts" in the E.U. The analyst notes that he is also lowering his FY19 revenue forecasts to $33.9B from $34.5B to reflect his updated lower HCV global market model and lower Mavyret sales from lower volumes. Boris also keeps his Buy rating on AbbVie longer term, citing potential benefits from the Imbruvica/Venclexta uptake/label expansion and any incremental M&A under incoming CFO Rob Michael.
10/19/18
FBCO
10/19/18
NO CHANGE
Target $85
FBCO
Underperform
AbbVie's 'surprise' CFO change raises more questions, says Credit Suisse
After AbbVie announced this morning that CFO Bill Chase will retire in mid-2019 and be replaced by the current Controller Robert Michael, Credit Suisse analyst Vamil Divan said he was "surprised" by the news for several reasons. He does not recall recent commentary from the company suggesting a CFO transition was in the works; he does not believe the Street had been expecting a CFO transition; the change is clearly happening at a sensitive time, given the launch of biosimilar versions of Humira in Europe this week and increasing questions around the mid-to-long term growth outlook for Humira in the U.S.; and this news was disclosed in an 8-K with no accompanying press release, Divan noted. While comments reinforcing the company's views on its longer-term outlook are "not required" in this case, they would have made Divan feel more comfortable that this was a well-planned transition, he added. The analyst keeps an Underperform rating and $85 price target on AbbVie shares, which are down 1% to $88.88.
10/02/18
PIPR
10/02/18
NO CHANGE
Target $100
PIPR
Neutral
AbbVie scripts for Humira relatively weak in Q3, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond says new survey data from dermatologists and gastroenterologists indicate AbbVie's (ABBV) Humira is losing share faster in psoriasis and inflammatory bowel disease than in rheumatoid arthritis. In that management has called out psoriasis as a key driver of growth, the survey feedback may help explain Humira's relatively weak script trends for Q3, Raymond tells investors in a research note. The analyst believes dermatologists are embracing newer biologics such as Johnson & Johnson's (JNJ) Tremfya while gastroenterologists favor Takeda's Entyvio and increasingly Pfizer's (PFE) Xeljanz. Raymond remains cautious on shares of AbbVie ahead of European biosimilar erosion he expects to start this month. He keeps a Neutral rating on the stock with a $100 price target.
ALXN Alexion
$122.99

-0.92 (-0.74%)

10/10/18
10/10/18
UPGRADE

Strong Buy
RA Pharmaceuticals upgraded to Strong Buy ahead of Phase 2 data at Raymond James
As previously reported, Raymond James upgraded RA Pharmaceuticals (RARX) to Strong Buy from Outperform with a $28 price target. Analyst Steven Seedhouse expects Phase 2 data for lead subcutaneous C5 inhibitor zilucoplan in generalized myasthenia gravis expected around YE18 to demonstrate a treatment benefit in a mixed refractory/non-refractory patient population and be competitive with Alexion's (ALXN) Soliris. Seedhouse believes a positive Phase 2 readout could be worth $1B in market cap at least and could treat a broader population of patients than Soliris given subcutaneous administration and pricing leverage.
09/28/18
LEHM
09/28/18
NO CHANGE
Target $175
LEHM
Overweight
Alexion price target raised to $175 from $165 at Barclays
Barclays analyst Geoff Meacham raised his price target for Alexion Pharmaceuticals to $175 saying this week's positive Phase 3 of Soliris data in neuromyelitis optica spectrum disorder "was a positive surprise for many and is the latest in a string of 'wins' for the company." The analyst thinks Alexion remains one of the more compelling names in biotech and he keeps an Overweight rating on the shares.
09/27/18
NOMU
09/27/18
NO CHANGE
Target $161
NOMU
Buy
Alexion acquisition bodes well for Argenx, says Nomura Instinet
Nomura Instinet analyst Christopher Marai believes Alexion Pharmaceuticals' (ALXN) acquisition of Syntimmune highlights potential demand for FcRn therapies by acquirers and bodes well for Argenx (ARGX). The analyst keeps a Buy rating on Argenx with a $161 price target.
10/15/18
PIPR
10/15/18
NO CHANGE
PIPR
Piper lists names to own in Biopharma after recent selloff
Piper Jaffray's biopharma analyst team highlighted names to own in the Biopharma sector following the recent selloff of the broader market. The firm's ideas include: Adamas Pharmaceuticals (ADMS), Agios Pharmaceuticals (AGIO), Agios Pharmaceuticals (ALNY), Alexion (ALXN), Bluebird Bio (BLUE), BioMarin (BMRN), CymaBay (CBAY), Crispr Therapeutics (CRSP), Global Blood Therapeutics (GBT), Horizon Pharma (HZNP), Jazz Pharmaceuticals (JAZZ), Ocular Therapeutix (OCUL), Rigel Pharmaceuticals (RIGL) and Xencor (XNCR).
AMGN Amgen
$197.54

-0.5 (-0.25%)

09/17/18
FBCO
09/17/18
NO CHANGE
Target $26
FBCO
Neutral
Teva price target raised to $26 from $23 at Credit Suisse
Credit Suisse analyst Vamil Divan reiterated a Neutral rating on Teva Pharmaceutical (TEVA) and raised his price target to $26 after the company said it received FDA approval for Ajovy, a key pipeline drug for migraine prevention and approval of a quarterly dosing for the drug, providing an important point of differentiation relative to competitors from Eli Lilly (LLY) and Amgen (AMGN)/Novartis (NVS). In a research note to investors, Divan says Friday's approval provides Teva with an important potential growth driver as it looks to overcome the challenges it faces with U.S. generics, Copaxone and its large debt load, and expects a "strong" positive reaction in the stock. Divan says he will look to see how Teva commercializes Ajovy in the coming months before becoming more constructive on the stock's longer-term outlook.
09/19/18
LEER
09/19/18
NO CHANGE
LEER
Outperform
Leerink 'incrementally positive on state of generics industry following meetings
Leerink analyst Ami Fadia tells investors in a research note that she is "incrementally positive" on the state of the generics industry following investor meetings with the management teams from Outperform-rated Amneal (AMRX), Pfenex and Teligent. Fadia says a key takeaway from the teams is that the FDA is placing additional emphasis on reviewing and approving complex generics, and while there is starting to be more first-to-market approvals, there are also more approvals for the second and third generic entrants. Additionally, Fadia says the complex generic opportunity will likely be characterized by a slower-than-typical launch ramp, but also extended duration of meaningful financial contribution due to less overall competitors vs that for oral-solid generics and that while companies still regard biosimilar assets as attractive, the low penetration for biosimilar Remicade in the U.S., Mylan's (MYL) slow start with Fulphila and extended litigation timelines mean management teams looking to participate in this space are taking a more prudent approach and minimizing their upfront investment.
10/01/18
CANT
10/01/18
INITIATION
Target $223
CANT
Neutral
Amgen initiated with a Neutral at Cantor Fitzgerald
Cantor Fitzgerald analyst Alethia Young started Amgen with a Neutral rating and $223 price target.
09/28/18
WELS
09/28/18
NO CHANGE
WELS
Market Perform
Lilly's migraine treatment approval adds to Teva worries, says Wells Fargo
Wells Fargo analyst David Maris noted that Eli Lilly (LLY) received FDA approval of Emgality for the prevention of migraines and announced a U.S. list price of $6,900 annually, which is in line with Teva's (TEVA) Ajovy and Aimovig from Amgen (AMGN) and Novartis (NVS). Lilly's approval adds to Teva investor worries, said Maris, who sees migraines being a competitive market with similar drugs "where the competitors are marketing powerhouses...and Teva is undergoing a lot of organizational change." He maintains a Market Perform rating on Teva shares.
AUPH Aurinia Pharmaceuticals
$5.29

-0.14 (-2.58%)

03/16/18
CANT
03/16/18
NO CHANGE
Target $16
CANT
Overweight
Aurinia price target raised to $16 from $14 at Cantor Fitzgerald
Cantor Fitzgerald analyst Elemer Piros raised his price target for Aurinia Pharmaceuticals to $16 citing a reduction of the company's estimated tax rate to 21% from 35% following its Q4 results. Aurinia remains on track to enroll its Phase 3 Aurora study in Q4 and to initiate studies to advance its pipeline indications for voclosporin in Q2, Piros tells investors in a research note. He reiterates an Overweight rating on the shares.
10/30/17
HCWC
10/30/17
NO CHANGE
Target $12
HCWC
Buy
Aurinia Pharmaceuticals price target raised to $12 from $10 at H.C. Wainwright
H.C. Wainwright analyst Ed Arce raised his price target for Aurinia Pharmaceuticals to $12 after the company at its recent analyst day announced plans to expand voclosporin development to include focal segmental glomerulosclerosis and minimal change disease. The analyst maintains a Buy rating on the shares.
02/08/18
RBCM
02/08/18
INITIATION
Target $9
RBCM
Outperform
Aurinia Pharmaceuticals initiated with an Outperform at RBC Capital
RBC Capital analyst Douglas Miehm initiated Aurinia Pharmaceuticals with an Outperform rating and a price target of $9. The analyst says the stock represents an "attractive opportunity with upside" based on the Phase 3 study of its lupus nephritis drug voclosporin, which "has potential to become the first FDA-approved treatment for the disease".
08/13/18
HCWC
08/13/18
NO CHANGE
Target $15
HCWC
Buy
Aurinia Pharmaceuticals price target raised to $15 from $12 at H.C. Wainwright
H.C. Wainwright analyst Ed Arce raised his price target for Aurinia Pharmaceuticals to $15 after the company announced its pivotal Phase 3 study of voclosporin in lupus nephritis patients is running ahead of schedule. The analyst view the progress as a reflection of the high level of interest and motivation in the trial, by both patients and investigators. He keeps a Buy rating on Aurinia shares.
BMY Bristol-Myers
$50.63

-0.24 (-0.47%)

10/22/18
10/22/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. eBay (EBAY) downgraded to Neutral from Buy at Monness Crespi and BofA/Merrill. 2. Bristol-Myers (BMY) downgraded to Neutral from Buy at Citi. 3. Manpower (MAN) downgraded to Neutral from Overweight at JPMorgan with analyst Andrew Steinerman saying he "misjudged the magnitude" of the European softness for the company as its Q4 financial guidance suggests a down 2% year-over-year same day basis revenue decline. 4. Reliance Steel (RS) downgraded to Neutral from Buy at Longbow with analyst Chris Olin citing near-term risks from unfavorable nonferrous demand/price momentum following a collection of relatively weak data points from the firm's carbon and stainless steel surveys. 5. Wingstop (WING) downgraded to Neutral from Outperform at Wedbush with analyst Nick Setyan saying he continues to believe drivers of same-store sales growth, unit growth, and margin upside relative to current consensus 2018 and 2019 estimates exist. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/23/18
WOLF
10/23/18
INITIATION
Target $66
WOLF
Outperform
Bristol-Myers reinitiated with an Outperform at Wolfe Research
Wolfe Research analyst Time Anderson reinitiated Bristol-Myers with an Outperform and $66 price target.
10/22/18
SBSH
10/22/18
DOWNGRADE
Target $57
SBSH
Neutral
Citi sees Merck showing 'extraordinary' treatment effect, downgrades Bristol
Citi analyst Andrew Baum downgraded Bristol-Myers Squibb (BMY) to Neutral from Buy and lowered his price target for the shares to $57 from $62. The drugmaker closed Friday down 3%, or $1.72, to $54.30. The downgrade largely reflects further likely "lowering of floor" Opdivo, Yervoy and earnings estimates from a base that is already materially below the consensus, Baum tells investors in a research note partially titled "The Final Straws." The analyst anticipates an "extraordinary" treatment effect from Keytruda in Merck's (MRK) Keynote-426 trial in renal cell carcinoma given the statistical significance for both progression-free survival and overall survival at the first interim analysis.
10/22/18
HCWC
10/22/18
NO CHANGE
Target $54
HCWC
Neutral
Roche data should concern Nektar bulls, says H.C. Wainwright
H.C. Wainwright analyst Debjit Chattopadhyay believes Roche's (RHHBY) preliminary data of RO6875281, a fibroblast activation protein targeted interleukin-2 variant, should concern the bulls of Nektar Therapeutics (NKTR). The 11% and 20% overall response rate for single agent RO6875281 in squamous cell head and neck cancer and melanoma is compelling, Chattopadhyay tells investors in a research note. Nektar's NKTR-214 had no monotherapy activity, and the early promise in combination with Opdivo "has faded potentially due to its limited PK profile," the analyst adds. In addition, Chattopadhyay believes the monotherapy activity with pegilodecakin, a pegylated IL-10 being developed by Eli Lily (LLY), further complicates the competitive landscape for NKTR-214. He believes the second generation of "not alpha" IL-2, which is poised to enter the clinic during 2019, could further "upend" NKTR-214 and might compel Nektar's partner Bristol-Myers Squibb (BMY) to "re-evaluate the aggressive development strategy that was outlined earlier this year." The analyst keeps a Neutral rating on Nektar with a $54 price target.
CELG Celgene
$79.75

-0.84 (-1.04%)

10/09/18
FBCO
10/09/18
NO CHANGE
FBCO
Outperform
Forty Seven selloff on Celgene trial ending seems premature, says Credit Suisse
After Celgene (CELG) disclosed the termination of its trial for CC-90002, an IgG4 construct that targets CD47, in acute myeloid leukemia and myelodysplastic syndrome patients, Credit Suisse analyst Martin Auster said the associated selloff in shares of Forty Seven (FTSV) seems premature to him. He does not believe the discontinuation in AML/MDS has a negative read-through to Forty Seven's 5F9 profile to date or its development in other indications, Auster tells investors. The analyst, who keeps an Outperform rating on Forty Seven shares, still sees promising efficacy in NHL providing a strong valuation base with substantial upside potential offered as 5F9 efficacy data matures.
09/12/18
FBCO
09/12/18
NO CHANGE
FBCO
Neutral
Bristol-Myers' TYK2 efficacy looks better than Otezla, says Credit Suisse
After Bristol-Myers (BMY) presented Phase 2 data for its oral TYK2 inhibitor, BMS-986165, in moderate-to-severe psoriasis at the EAVD meeting, Credit Suisse analyst Vamil Divan said he believes the "robust" data are very encouraging for the ongoing Phase 3 studies. BMS-986165 achieved PASI 75 response rates that are better than what was demonstrated by Celgene's (CELG) Otezla and the safety profile "appears reasonable," Divan tells investors. While BMS-986165 could be highly competitive clinically against other oral treatments, the crowded psoriasis market remains a tough one for new products, added the analyst, who keeps a Neutral rating on Bristol-Myers shares.
10/01/18
CANT
10/01/18
INITIATION
Target $100
CANT
Overweight
Celgene initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Alethia Young started Celgene with an Overweight rating and $100 price target.
09/20/18
HCWC
09/20/18
NO CHANGE
Target $2
HCWC
Neutral
OncoMed price target lowered to $2 after Celgene pass at H.C. Wainwright
H.C. Wainwright analyst Edward White lowered his price target on OncoMed (OMED) shares to $2 from $3 after partner Celgene (CELG) passed on its option to license navicixizumab. Worldwide development, commercialization and rights to navicixizumab now remain under OncoMed's control while Celgene retains options to license OncoMed's anti-TIGIT monoclonal antibody, etigilimab, and anti-RSPO3, rosmantuzumab, noted White. The analyst, who notes there is potential the company could partner the asset, keeps a Neutral rating on OncoMed shares.
DGX Quest Diagnostics
$95.19

-6.34 (-6.24%)

10/23/18
PIPR
10/23/18
NO CHANGE
Target $110
PIPR
Neutral
Quest Diagnostics key metrics weaker than expected, says Piper Jaffray
Piper Jaffray analyst William Quirk says shares of Quest Diagnostics are trading down 6% after announcing in-line Q3 earnings with a revenue shortfall this morning. Management reduced guidance for the ongoing challenges with hepatitis C virus volumes, prescription drug monitoring and vitamin D payments, Quirk tells investors in a post-earnings research note titled "3Q18 A Web Of Moving Parts; Bottom Line - Weaker Key Metrics - Remain Neutral." The analyst keeps a Neutral rating on Quest shares with a $110 price target citing stronger than expected pricing headwinds.
10/19/18
BOFA
10/19/18
INITIATION
Target $116
BOFA
Buy
Quest Diagnostics reinstated with a Buy at BofA/Merrill
BofA/Merrill analyst Derik de Bruin reinstated Quest Diagnostics with a Buy and $116 price target saying valuation is undemanding. de Bruin sees upside from Medicare reimbursement cuts which should result in lab consolidation, monetization of lab data, and retail clinic opportunities.
09/25/18
PIPR
09/25/18
NO CHANGE
PIPR
Piper sees early winners from annual list of new codes from CMS
The Centers for Medicare & Medicaid Services published its annual list of new codes ahead of the final rate determination including 99 codes, Piper Jaffray analyst William Quirk tells investors in a research note. He says Genomic Health (GHDX), LabCorp (LH), Myriad Genetics (MYGN), Natera (NTRA) and Quest Diagnostics (DGX) look like early winners in the 2019 Preliminary Clinical Laboratory Fee Schedule Fee Schedule determinations, with an incrementally positive competitive move for CareDx (CDNA). The analyst notes that Genomic Health received increased reimbursement for a couple tests and CareDx competitor TAI Diagnostics ends up with a likely longer pathway to reimbursement.
09/25/18
PIPR
09/25/18
NO CHANGE
PIPR
Piper Jaffray confident on Oxford path to profitability after Quest deal
Piper Jaffray analyst William Quirk notes that Quest Diagnostics (DGX) announced the acquisition of the U.S. laboratory services business from Oxford Immunotec (OXFD), paying $170M for about $55M in tick-borne disease and TB revenue. The deal streamlines Oxford Immunotec into essentially a kit company with better margins and an opportunity to vie for Qiagen's attractive Quest business, he contends, adding that the TB market has been growing in the mid-teens in the U.S., largely converting existing volume from the skin test to the more accurate IGRA class of assays. Long-term, Quirk believes Oxford's revenue estimates may be more predictable than they have been in the past, and his confidence in the company's path to profitability is improved following the deal announcement.
DNA Bought by RHHBY
$0.00

(0.00%)

FLXN Flexion
$16.66

-0.57 (-3.31%)

08/08/18
WELS
08/08/18
NO CHANGE
Target $39
WELS
Outperform
Flexion Q2 suggests Zilretta launch proceeding as expected, says Wells Fargo
Wells Fargo analyst David Maris kept his Outperform rating and $39 price target on Flexion, saying the company's Q2 results suggest that Zilretta sales are proceeding according to its plans and in line with his expectations. The analyst points to the management's comments that the overall response on Zilretta from physicians has been positive, adding that its unique product specific Q-code becoming effective as of this July 1st will drive sales growth in the second half of 2018.
10/22/18
WELS
10/22/18
NO CHANGE
Target $39
WELS
Outperform
Flexion 'very attractively priced' after selloff, says Wells Fargo
Wells Fargo analyst David Maris believes the main driver for today's selloff in shares of Flexion Therapeutics to Centrexion filing Friday to go public. Centrexion has a potential competing drug to Flexion and is pursuing a unique strategy using an injection of a synthetically derived form of the active ingredient found in chili peppers that is responsible for the burning sensation, Maris tells investors in a research note. However, he's not convinced that Centrexion's drug will be a competitor to Flexion's Zilretta. Centrexion's drug requires a significant lead-time for the injection as the doctor needs to numb the knee prior to injection, Maris points out. He adds that "cooling of the knee" is needed, as without it, the injection is very painful. He believe this makes Centrexion's drug "a commercial challenge." Overall, the recent selloff in Centrexion "has made a promising company very attractively priced," writes Maris. With a J-code hitting in January allowing for automatic reimbursement, he expects an inflection to sales in 2019, and with that, an improving share performance. The analyst keeps an Outperform rating on Flexion Therapeutics with a $39 price target.
06/28/18
BNCH
06/28/18
INITIATION
Target $39
BNCH
Buy
Flexion initiated with a Buy at Benchmark
Benchmark started Flexion Therapeutics with a Buy rating and $39 price target.
06/28/18
06/28/18
INITIATION
Target $39

Buy
Benchmark says Zilretta can be 'best-in-class,' starts Flexion at Buy
As previously reported, Benchmark analyst Bruce Jackson initiated Flexion Therapeutics with a Buy rating and $39 price target, citing his belief that Zilretta can emerge as a "best-in-class" therapy for treating osteoarthritis knee pain. He sees peak sales potential in excess of $750M for the drug, he tells investors in his initiation note.
GILD Gilead
$71.64

-0.71 (-0.98%)

10/05/18
SBSH
10/05/18
NO CHANGE
SBSH
Gilead may need Dicerna after Arrowhead, J&J deal, says Citi
Given the partnership announced yesterday between Arrowhead Pharmaceuticals (ARWR) and Johnson & Johnson (JNJ), Gilead Sciences' (GILD) hepatitis B virus portfolio may need another component and Dicerna Pharmaceuticals (DRNA) "could be one of them," Citi analyst Robyn Karnauskas tells investors in a research note. The analyst believes large pharma and Gilead are "still missing a key piece to bring a curative therapy to market that can rapidly and effectively lower HBsAg." The Arrowhead deal makes it apparent that HBV portfolios may need a multi-target approach and validates the RNAi platform to target HBV, the analyst contends.
10/02/18
JEFF
10/02/18
NO CHANGE
Target $135
JEFF
Buy
Jefferies sees Intercept moving higher after 'mixed' Gilead data
Jefferies analyst Michael Yee views Gilead Sciences' (GILD) new six-month nonalcoholic steatohepatitis data as "mixed and undifferentiated." As such, he thinks shares of Intercept Pharmaceuticals (ICPT) probably continue to move higher. The stock is likely to retrace back up into year-end and the first half of 2019 as Street realizes Intercept's Phase III will be positive and de-risked, Yee tells investors in a research note. He says the company has had various competitor Farnesoid X receptor data in Phase I/II read out over the past year or and that these have ended up not too differentiated. This has removed some of the competitive overhang on Intercept, the analyst contends. Yee keeps a Buy rating on the shares with a $135 price target.
10/01/18
CANT
10/01/18
INITIATION
Target $87
CANT
Overweight
Gilead initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Alethia Young started Gilead Sciences with an Overweight rating and $87 price target.
09/25/18
JEFF
09/25/18
INITIATION
Target $75.5
JEFF
Buy
Cambrex initiated with a Buy at Jefferies
Jefferies analyst David Windley started Cambrex (CBM) with a Buy rating and $75.50 price target. The analyst sees the company, as a leading manufacturer of small molecule active pharmaceutical ingredients, benefiting from increased API outsourcing. He adds that his Gilead (GILD) analysis, Cambrex's top customer, is "differentiated and positive."
GSK GlaxoSmithKline
$40.63

0.12 (0.30%)

09/19/18
MSCO
09/19/18
NO CHANGE
MSCO
Equal Weight
Morgan Stanley says AbbVie market cap fell more than largest drug settlement
After AbbVie (ABBV) slid about 3% yesterday following a California Insurance Commissioner lawsuit alleging Humira kickbacks, Morgan Stanley analyst David Risinger noted its $4B loss in market cap was larger than GlaxoSmithKline's (GSK) previous $3B settlement for violations under the False Claims Act, which he called the biggest ever historical pharma settlement. While Commissioner Dave Jones claims imply that the potential fine for Abbvie could theoretically be more than $3B, Risinger also noted that the company told him it believes the allegations "are completely without merit." He maintains an Equal Weight rating and $100 price target on AbbVie shares.
10/08/18
GUGG
10/08/18
INITIATION
GUGG
Neutral
GlaxoSmithKline initiated with a Neutral at Guggenheim
Guggenheim analyst Seamus Fernandez started GlaxoSmithKline with a Neutral rating and 1,679p price target, stating that he views its upside more in the consumer side than in pharma. The company's oncology and immunology pipeline could emerge, but it is still a bit early to tell, Fernandez added in his initiation note.
10/16/18
WELS
10/16/18
NO CHANGE
WELS
Drug price in ads not impactful, may cause confusion, says Wells Fargo
Wells Fargo analyst David Maris acknowledges that the U.S. Department of Health and Human Services' proposal to include drug prices in advertisements has a "noble goal" of making drugs more affordable and keeping patients well informed. However, given how different list prices are relative to out of pocket costs, "one must ask if this is increasing transparency or likely going to lead to more confusion," he contends. The analyst also believes that the unintended consequence could be worse care, while noting that the drug price information will likely fall into the category of the side effect information in drug ads currently, tuned out by many and will have no material impact. While he supports the idea of increased transparency, Maris wonders whether the potential benefit is not outweighed by the potential negative for the most vulnerable. Publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
10/23/18
WOLF
10/23/18
INITIATION
WOLF
Peer Perform
GlaxoSmithKline reinitiated with a Peer Perform at Wolfe Research
Wolfe Research analyst Time Anderson reinitiated GlaxoSmithKline with a Peer Perform.
REGN Regeneron
$380.37

-7.79 (-2.01%)

10/17/18
JEFF
10/17/18
NO CHANGE
Target $31
JEFF
Buy
Jefferies still sees 'major' opportunity for Optinose after Dupixent data
Optinose (OPTN) shares underperformed yesterday following the positive Phase 3 results for Sanofi (SNY) and Regeneron's (REGN) Dupixent in treating patients with chronic rhinosinusitis with nasal polyps, Jefferies analyst David Steinberg tells investors in a research note titled "Biologics Competitor as Expected; Real World Pricing Issues Likely to Limit Us." The analyst says that while Dupixent demonstrated strong efficacy, clinicians he's spoken with believe that the "massive" pricing disparity versus nasal steroids will likely result in payer "step edits" that could limit widespread adoption of the "expensive" biologics currently under development. Further, Dupixent's head-to-head comparison with Optinose's Xhance's "strong" efficacy profile is difficult, the analyst adds. Steinberg still sees a "major" long-term opportunity for Xhance and keeps a Buy rating on Optinose with a $31 price target.
10/16/18
LEER
10/16/18
NO CHANGE
LEER
Outperform
Regeneron data won't derail Intersect ENT's Sinuva, says Leerink
Leerink analyst Richard Newitter attributes the underperformance today in shares of Intersect ENT (XENT) to Regeneron's (REGN) positive Phase 3 Dupixent data for chronic rhinosinusitis with nasal polyps. The Dupixent readout had always represented a potential headline risk for Intersect ENT during Q4, Newitter tells investors in a research note. The analyst, however, thinks it's better to get the headline out of the way before a J-code decision in early November. Further, based on physician feedback around monoclonal antibodies, Newitter does not get the sense that these therapies will "necessarily derail" adoption of Intersect ENT's Sinuva or its total addressable market. The analyst continues to believe in-line Q3 results will be a "win" for Intersect ENT and he keeps an Outperform rating on the shares. The stock in afternoon trading is down 68c to $29.24.
10/22/18
PIPR
10/22/18
NO CHANGE
Target $450
PIPR
Overweight
Regeneron asthma label for Dupixent broad as hoped, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond says that while Regeneron Pharmaceuticals' asthma label for Dupixent does not broadly cover patients regardless of eosinophilic phenotype as he had anticipated, it does cover oral corticosteroid dependent patients regardless of eosinophilic phenotype, which essentially matches his modeling. Moreover, the analyst notes that the label covers all patients 12 and older, and both moderate and severe disease. As such, he sees the label as broad, "but not necessarily as anticipated." The analyst is making no change to his numbers based on the label and keeps an Overweight rating on Regeneron with a $450 price target.
10/22/18
CANT
10/22/18
NO CHANGE
Target $441
CANT
Neutral
Regeneron price target raised to $441 from $419 at Cantor Fitzgerald
Cantor Fitzgerald analyst Alethia Young raised her price target for Regeneron Pharmaceuticals to $441 citing Dupixent's label in asthma, which she thinks is broad. The analyst believes the shares could trade up 5% on the label but she keeps a Neutral rating on the name. Dupixent expectations are high already, Young tells investors in a research note.
RARE Ultragenyx
$61.53

-0.56 (-0.90%)

08/29/18
JPMS
08/29/18
NO CHANGE
JPMS
Overweight
Ultragenyx filing allowance 'a clear step in right direction,' says JPMorgan
JPMorgan analyst Cory Kasimov said the announcement that UX007 can be filed for fatty acid oxidation disorders based primarily on Phase 2 data is "a clear step in the right direction" and he expects the news to help maintain the company's positive near-term momentum. FAOD could represent a billion-dollar-plus market, but Kasimov said he is maintaining his more conservative $300M peak sales forecast and 50% odds of success pending additional clarity on today's FDA filing allowance news. The analyst, who notes that Phase 3 data for UX007 in Glut1 DS, which is a potentially even larger market, is anticipated in the second half, keeps his Overweight rating on Ultragenyx shares.
08/30/18
WEDB
08/30/18
NO CHANGE
Target $90
WEDB
Outperform
Ultragenyx price target raised to $90 from $80 at Wedbush
Wedbush analyst David Nierengarten raised his price target for Ultragenyx to $90 from $80, while reiterating an Outperform rating on the shares. With FDA appearing to be favorably disposed toward early approval of UX007 in long-chain fatty acid oxidation disorders, the analyst is advancing his launch time to late 2019 from first half of 2021 and reducing discount rate to 20% from 25%.
09/27/18
PIPR
09/27/18
NO CHANGE
PIPR
Overweight
Ultragenyx given little credit for gene therapy efforts, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond finds it "somewhat puzzling" that investors appear to be giving Ultragenyx little credit for its gene therapy efforts despite the early clinical signals of efficacy seen from DTX301 after data from two cohorts of its ongoing Phase 1/2 study. He thinks this may start to change with more readouts for DTX401 in the second half of 2018 and for DTX301 in mid-2019. On DTX301 gene therapy for ornithine transcarbamylase deficiency, Raymond thinks it "is a dosing matter" and awaits to see if a higher dose can in fact elicit more responses. He maintains an Overweight rating on Ultragenyx shares.
09/10/18
MSCO
09/10/18
INITIATION
Target $92
MSCO
Equal Weight
Ultragenyx assumed with an Equal Weight at Morgan Stanley
Morgan Stanley analyst Jeffrey Hung assumed coverage of Ultragenyx with an Equal Weight rating and $92 price target, stating that he believes expectations of strong launches for Mepsevii and Crysvita are largely priced into the shares. The company has a diverse pipeline, but most of it will take time to reach market, Hung added.
QDEL Quidel
$65.16

0.75 (1.16%)

10/23/18
RAJA
10/23/18
INITIATION
Target $80
RAJA
Strong Buy
Quidel resumed with a Strong Buy at Raymond James
Raymond James analyst John Hsu resumed coverage on Quidel with a Strong Buy and $80 price target telling investors it is one of the last remaining pure play diagnostics companies with a focus on point-of-care testing, and it has multiple tailwinds driving sustained mid-single-digit organic growth.
08/08/18
PIPR
08/08/18
NO CHANGE
Target $74
PIPR
Overweight
Quidel price target raised to $74 from $66 at Piper Jaffray
Piper Jaffray analyst William Quirk raised his price target for Quidel to $74 saying the in-line sales and earnings beat in Q2 does not tell the entire story. The acquired Cardiac business was well ahead of expectations and suggests further upside over the course of 2018, Quirk tells investors in a post-earnings research note. The analyst views the Q2 report as solid and reiterates an Overweight rating on Quidel.
09/10/18
ADAM
09/10/18
NO CHANGE
Target $80
ADAM
Buy
Quidel could draw interest from a larger company, says Canaccord
Canaccord analyst Mark Massaro remains positive on Quidel (QDEL) after hosting meetings with management. The analyst cited rising demand for its new products and he expects the company to continue to take market share from larger companies Alere (ABT) and Becton Dickinson (BDX). He also believes the company could draw interest from a larger company, like the bid Alere got from Abbott. Massaro reiterated his Buy rating and raised his price target to $80 from $78 on Quidel shares.
08/08/18
CHLM
08/08/18
NO CHANGE
Target $80
CHLM
Buy
Quidel price target raised to $80 from $64 at Craig-Hallum
Craig-Hallum analyst Alexander Nowak raised his price target for Quidel to $80 from $64 after another quarter of "solid" cardiac execution. However, the analyst notes that the upside was offset by lower Rapid Immunoassay sales, particular lower influenza revenue. He reiterates a Buy rating on the shares.
PFE Pfizer
$44.09

-0.28 (-0.63%)

10/08/18
GSCO
10/08/18
NO CHANGE
Target $36
GSCO
Sell
Ionis' Tegsedi to face commercial headwinds, says Goldman Sachs
After the FDA approved Ionis (IONS) and affiliate Akcea Therapeutics' (AKCA) Tegsedi for adult polyneuropathy of hereditary transthyretin-mediated amyloidosis, but with a black box warning, Goldman Sachs analyst Salveen Richter said he believes the drug faces commercial headwinds. He cites the underlying safety profile and requirement for consistent monitoring as well as the recent launch of Alnylam's (ALNY) Onpattro and expected launch of Pfizer's (PFE) tafamidis in the first half of 2019. Richter keeps a Sell rating on Ionis shares with a price target of $36.
10/23/18
WOLF
10/23/18
INITIATION
Target $46
WOLF
Peer Perform
Pfizer reinitiated with a Peer Perform at Wolfe Research
Wolfe Research analyst Time Anderson reinitiated Pfizer with a Peer Perform and $46 price target.
NVS Novartis
$88.01

0.89 (1.02%)

10/18/18
WEDB
10/18/18
DOWNGRADE
WEDB
Neutral
Endocyte downgraded to Neutral from Outperform at Wedbush
Wedbush analyst David Nierengarten downgraded Endocyte (ECYT) to Neutral after the company agreed to be acquired by Novartis (NVS) for $24 per share. The analyst does not next another bidder to emerge.
10/19/18
WELS
10/19/18
DOWNGRADE
WELS
Market Perform
Endocyte downgraded to Market Perform from Outperform at Wells Fargo
Wells Fargo analyst Jim Birchenough downgraded Endocyte (ECYT) to Market Perform from Outperform, citing the company's deal to be acquired by Novartis (NVS). He believes that the proposed acquisition price of $24 per share fairly reflects the potential value of the company's lead PSMA-targeted radionuclide therapeutic and sees Novartis as best positioned to realize that value based on its leadership in radionuclide therapeutics. Birchenough sees low odds of a competing offer and low risk of a material event to derail the acquisition, he added.
10/23/18
WOLF
10/23/18
INITIATION
WOLF
Outperform
Novartis reinitiated with an Outperform at Wolfe Research
Wolfe Research analyst Time Anderson reinitiated Novartis with an Outperform.
10/19/18
HCWC
10/19/18
NO CHANGE
Target $36
HCWC
Buy
Xoma 'undeservedly and overly punished' after CRL, says H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis lowered his price target for Xoma (XOMA) to $36 from $49 after the company's partner Novartis (NVS) disclosed the receipt of a Complete Response Letter from the FDA in response to its application for the claim of cardiovascular risk reduction filed for canakinumab. Though canakinumab is one of the lead contributors to Xoma's valuation, the company's shares have been "undeservedly and overly punished," Pantginis tells investors in a research note. He remains focused on Xoma continuing to diversify its risk profile, highlighted by its recent Agenus (AGEN) transaction. He believes the company's numerous "shots on goal" present a "compelling opportunity" at current share levels.
MRK Merck
$72.09

-0.47 (-0.65%)

10/23/18
WOLF
10/23/18
INITIATION
Target $90
WOLF
Outperform
Merck reinitiated with an Outperform at Wolfe Research
Wolfe Research analyst Time Anderson reinitiated Merck with an Outperform and $66 price target.
10/22/18
WBLR
10/22/18
NO CHANGE
WBLR
Merck data will dampen enthusiasm for Aduro Biotech, says William Blair
Merck (MRK) over the weekend presented the first-in-human data with a STING agonist, MK-1454, as monotherapy and in combination with Keytruda, William Blair analyst Matt Phipps tells investors in a research note. Overall, the lack of monotherapy responses and 24% overall response rate in combination with Keytruda across a variety of tumor types is "underwhelming" given the promising preclinical results seen with multiple STING agonists and industry enthusiasm for the target, the analyst contends. He believes investor enthusiasm for the upcoming poster with Aduro Biotech's (ADRO) STING agonist, ADU-S100, at the Society for the Immunotherapy of Cancer meeting "will undoubtedly be dampened." However, Phipps thinks it is premature to make final judgments on targeting STING in cancer immunotherapy based on Merck's small sample size of injections into one lesion. He has an Outperform rating on Aduro Biotech.
10/22/18
BMOC
10/22/18
NO CHANGE
Target $82
BMOC
Outperform
Merck price target raised to $82 from $70 at BMO Capital
BMO Capital analyst Alex Arfaei raised his price target on Merck to $82 and kept his Outperform rating, also raising his FY18 EPS view by 18c to $4.01 and FY19 view by 27c to $4.29. The analyst cites his increased confidence around the long-term growth potential of Keytruda and Gardasil and anticipates the company's revenue growing by mid-single digits until the loss of exclusivity for its Januvia program in 2022-23. Arfaei adds that his long-term forecasts are more bullish relative to the Street, with an added catalyst coming from Merck's potential diversification into Animal Health.
MCK McKesson
$127.25

0.54 (0.43%)

07/20/18
BARD
07/20/18
DOWNGRADE
BARD
Neutral
McKesson downgraded to Neutral from Outperform at Baird
07/20/18
BARD
07/20/18
DOWNGRADE
BARD
Neutral
Express Scripts, AmerisourceBergen, McKesson cut to Neutral at Baird
As previously reported, Baird analyst Eric Coldwell downgraded Express Scripts (ESRX), AmerisourceBergen (ABC) and McKesson (MCK), all to Neutral from Outperform, citing the heavy political attack in recent weeks against PBMs and members of the drug supply chain. Among them, he said AmerisourceBergen remains his preferred name, but he cannot justify putting new money to work in these names in the current environment, stating that visibility has deteriorated further across the supply chain.
07/20/18
07/20/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. BOFA CUTS YUM CHINA TO UNDERPERFORM: BofA Merrill Lynch analyst Chen Luo downgraded Yum China (YUMC) to Underperform from Neutral and cut its price target to $34 from $44.30. Luo said he expects Yum China to continue to underperform given a likely peak in KFC trends amid China's weakening macro environment, a likely prolonged turnaround at Pizza Hut combined with heavy costs, a slowdown in Chinese consumer consumption, and RMB depreciation. Yum China is down 4.8% in late morning trading. CREDIT SUISSE CUTS FIVE BELOW TO NEUTRAL: Credit Suisse analyst Judah Frommer downgraded Five Below (FIVE) to Neutral from Outperform, telling investors that he is moving to the sidelines as he sees risk/reward balanced at current levels given the stock's material outperformance and back-half comp acceleration that he believes is priced into shares. Frommer keeps his $110 price target and says Five Below remains one of the most differentiated concepts in retail. Five Below is down 4.4% in late morning trading. BAIRD MORE CAUTIOUS ON DRUG SUPPLY CHAIN: Baird analyst Eric Coldwell downgraded Express Scripts (ESRX), AmerisourceBergen (ABC), and McKesson (MCK), all to Neutral from Outperform, citing the heavy political attack in recent weeks against pharmacy benefit managers and members of the drug supply chain. Among them, he said AmerisourceBergen remains his preferred name, but he cannot justify putting new money to work in these names in the current environment. SUNTRUST STARTS VIKING WITH A BUY: SunTrust analyst Edward Nash initiated Viking Therapeutics (VKTX) with a Buy rating and a price target of $14, saying its VK2809 drug for lipid disorders "has the potential to become a promising treatment by addressing multiple metabolic issues" associated with the non-alcoholic steatohepatitis disease, or NASH. Viking is up 8.3% in late morning trading. JPMORGAN SAYS BUY GM, SELL TESLA INTO EARNINGS: JPMorgan analyst Ryan Brinkman forecast lower than consensus Q2 earnings for Ford (F) and higher than consensus earnings for General Motors (GM). The analyst is also concerned about the potential for a "large loss and accompanying large cash outflow" at Tesla (TSLA) in Q2 to "make the bridge" to GAAP profitability and positive cash generation in the second half of the year. Brinkman maintained Overweight ratings on GM and Ford, with a preference for GM shares. He also kept his cautious Underweight rating on Tesla shares, seeing 44% downside to his $180 December 2018 price target.
07/20/18
07/20/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Philip Morris (PM) downgraded to Neutral from Overweight at JPMorgan and to Market Perform from Outperform at Cowen. 2. Skechers (SKX) downgraded to Neutral from Positive at Susquehanna and to Market Perform from Outperform at Wells Fargo. 3. McKesson (MCK), AmerisourceBergen (ABC), and Express Scripts (ESRX) downgraded to Neutral from Outperform at Baird. 4. Five Below (FIVE) downgraded to Neutral from Outperform at Credit Suisse with analyst Judah Frommer saying he is moving to the sidelines as he sees risk/reward balanced at current levels given the stock's material outperformance and back-half comp acceleration that he believes is priced into shares. 5. Yum China (YUMC) downgraded to Underperform from Neutral at BofA/Merrill with analyst Chen Luo saying he expects Yum China to continue to underperform given a likely peak in KFC trends amid China's weakening macro environment, a likely prolonged turnaround at Pizza Hut combined with heavy costs, a slowdown in Chinese consumer consumption, and RMB depreciation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
LLY Eli Lilly
$110.41

-1.66 (-1.48%)

10/23/18
WOLF
10/23/18
INITIATION
Target $119
WOLF
Peer Perform
Eli Lilly reinitiated with a Peer Perform at Wolfe Research
Wolfe Research analyst Time Anderson reinitiated Eli Lilly with a Peer Perform and $119 price target.
10/15/18
FBCO
10/15/18
INITIATION
Target $36
FBCO
Neutral
Elanco initiated with a Neutral at Credit Suisse
Credit Suisse analyst Erin Wright started Elanco (ELAN) with a Neutral rating and $36 price target. As the fourth-largest animal health therapeutics company, Elanco is highly levered to robust industry fundamentals across livestock and companion animal markets, and earnings growth should accelerate on dedicated innovation efforts and dramatically improving cost structure as a more nimble unencumbered entity, unchained to Eli Lilly (LLY), its large pharmaceutical parent, she contends.
TMO Thermo Fisher
$223.46

-2.29 (-1.01%)

10/09/18
UBSW
10/09/18
NO CHANGE
UBSW
UBS initiates coverage of Life Sciences and Diagnostics Tools sector
UBS analyst Daniel Brennan initiated coverage of the Life Sciences and Diagnostics Tools sector. He said demand is accelerating across his universe but valuations are extended. He expects strong fundamentals to continue into 2019 but he said selectivity is the key. In the group, his Buy ratings include Exact Sciences (EXAS), Iqvia (IQV), NanoString (NSTG), Syneos Health (SYNH) and Thermo Fisher (TMO).
10/18/18
10/18/18
DOWNGRADE

Neutral
Follow-up: Thermo Fisher downgraded to Neutral at Cleveland Research
As previously reported, Cleveland Research downgraded Thermo Fisher to Neutral from Buy. Analyst Steve Willoughby said feedback indicates "extremely strong trends" in the industry are "unlikely to be sustained" at the same rate going into 2019. The analyst is now assuming softer than expected organic growth, less contribution from M&A, and FX headwinds. Willoughby is now slightly below consensus with his estimates and sees less upside in shares going forward.
10/18/18
CLVD
10/18/18
DOWNGRADE
CLVD
Neutral
Thermo Fisher downgraded to Neutral from Buy at Cleveland Research
10/09/18
UBSW
10/09/18
INITIATION
Target $295
UBSW
Buy
Thermo Fisher initiated with a Buy at UBS
UBS analyst Daniel Brennan initiated Thermo Fisher with a Buy rating and $295 price target.
TKPYY Takeda Pharmaceutical
$0.00

(0.00%)

09/04/18
09/04/18
DOWNGRADE

Market Perform
Shire downgraded to Market Perform as spread narrows at Bernstein
As previously reported, Bernstein analyst Aaron Gal downgraded Shire (SHPG) to Market Perform from Outperform. The analyst notes that he current controversy on Shire is the risk/reward into the closing of the Takeda (TKPYY) acquisition, and over the past few weeks deal spread narrowed, and the fundamentals have gotten a bit tougher in ADHD, HAE and Hemophilia.
09/07/18
BREN
09/07/18
DOWNGRADE
BREN
Hold
Shire downgraded to Hold from Buy at Berenberg
Berenberg analyst Klara Fernandes downgraded Shire (SHPG) to Hold saying the current valuation offers limited potential upside ahead of the pending takeover by Takeda Pharmaceutical (TKPYY).
05/09/18
LEER
05/09/18
NO CHANGE
LEER
Takeda/Shire transaction shows path for consolidation, says Leerink
Leerink analyst Geoffrey Porges notes that Takeda (TKPYY) confirmed its intention and agreement to purchase Shire (SHPG) for $62B in cash and stock. For the broader biopharma industry, the analyst believes Takeda's ability to lever up to an estimated 5.4x net debt/EBITDA suggests that investors are underestimating the ability of large cap biopharma companies to pursue large transactions. Nearly all of the large cap biopharma companies face looming growth issues or suffer under revenue-concentration risk discounts that could be mitigated by large-scale acquisitions, he contends. Porges believes that if Takeda can execute the Shire acquisition while checking the boxes of investor demands of a net positive ROIC, instant EPS accretion, maintaining an investment grade credit rating, and massive synergy savings, then others in the biopharma industry with stronger balance sheets and larger valuations can contemplate transactions that are substantially larger even than Shire.
04/25/18
RHCO
04/25/18
NO CHANGE
Target $205
RHCO
Buy
Shire price target raised to $205 from $190 at SunTrust
SunTrust analyst John Boris raised his price target on Shire (SHPG) to $205 and kept his Buy rating after an updated merger proposal from Takeda (TKPYY), which has until May 8th to make the final offer. Boris believes the combined stock-and-cash offer of $205 is high enough for Shire shareholders to accept the terms, and other bidders could potentially emerge based on its positive catalysts such as Neuroscience strategic review and LANA August PDUFA.
SELB Selecta Biosciences
$8.91

-4.46 (-33.36%)

10/23/18
ADAM
10/23/18
NO CHANGE
ADAM
Selecta Biosciences weakness a buying opportunity, says Canaccord
10/23/18
STFL
10/23/18
NO CHANGE
STFL
Buy
Selecta SEL-212 data 'very competitive to Krystexxa mono/combo therapy, says Stifel
Stifel analyst Derek Archila views Selecta Biosciences (SELB) SEL-212 Phase 2 data in chronic severe gout as positive and thinks it represents a "very competitive" emerging profile relative to the incumbent brand, Horizon Pharma's (HZNP) Krystexxa. The analyst comes away positive with the fact SEL-212's projected response rate remains competitive on a modified intent-to-treat basis, SVP-Rapamycin was tolerable out to five months of dosing, and SEL-212's rate of gout flares was lower than Krystexxa alone and Krystexxa+methotrexate early on. Archila remains positive on the stock and believes SEL-212 could offer an improvement to the current standard of care for chronic severe gout. Further, Archila does not believe shares fully reflect the program's commercial potential and reiterates a Buy rating on Selecta's shares.
10/23/18
MZHO
10/23/18
NO CHANGE
Target $30
MZHO
Buy
Selecta stock reaction to SEL-212 data 'overly negative,' says Mizuho
Mizuho analyst Difei Yang believes the market reaction to Selecta Biosciences' (SELB) Phase 2 data on SEL-212 is "overly negative," stating that she believe it is likely acceptable to the FDA to proceed into Phase 3. While not as good as she had hoped for, she still sees the data remaining superior to standalone Krystexxa, marketed by Horizon Pharma (HZNP), "especially considering stringent stopping rules and evaluation criteria in the trial," Yang tells investors. She keeps a Buy rating and $30 price target on Selecta shares.
10/23/18
JANY
10/23/18
NO CHANGE
JANY
Buy
Selecta Biosciences weakness an 'overreaction,' says Janney Montgomery Scott

TODAY'S FREE FLY STORIES

12:25
12/13/18
12/13
12:25
12/13/18
12:25
Conference/Events
UBS alternative energy analyst to hold an analyst/industry conference call »

Alternative Energy…

CSTM

Constellium

$8.19

-0.22 (-2.62%)

12:25
12/13/18
12/13
12:25
12/13/18
12:25
Conference/Events
Constellium to host analyst day »

Analyst Day to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 17

    Dec

  • 18

    Dec

SBUX

Starbucks

$66.32

0.22 (0.33%)

12:25
12/13/18
12/13
12:25
12/13/18
12:25
Conference/Events
Starbucks to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 14

    Dec

BABA

Alibaba

$151.67

0.18 (0.12%)

, YOKU

Youku Tudou

$0.00

(0.00%)

12:23
12/13/18
12/13
12:23
12/13/18
12:23
Hot Stocks
Alibaba's Youku to host highlights, documentary content from NFL »

Youku (YOKU), the Alibaba…

BABA

Alibaba

$151.67

0.18 (0.12%)

YOKU

Youku Tudou

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Mar

FIZZ

National Beverage

$79.84

-4.28 (-5.09%)

, STZ

Constellation Brands

$182.12

-4.58 (-2.45%)

12:21
12/13/18
12/13
12:21
12/13/18
12:21
Conference/Events
UBS beverages analyst to hold an analyst/industry conference call »

Beverages Analyst Sean…

FIZZ

National Beverage

$79.84

-4.28 (-5.09%)

STZ

Constellation Brands

$182.12

-4.58 (-2.45%)

PEP

PepsiCo

$118.01

1.03 (0.88%)

CCE

Coca-Cola European Partners

$0.00

(0.00%)

BFB

Brown-Forman, also tag with BF.A, BF.B

$0.00

(0.00%)

BFA

Brown-Forman, also tag with BF.A, BF.B

$0.00

(0.00%)

BF.B

Brown-Forman, also tag with BFA, BFB

$46.92

0.44 (0.95%)

MNST

Monster Beverage

$53.60

-3.84 (-6.69%)

SAM

Boston Beer

$263.73

-10.35 (-3.78%)

KDP

Keurig Dr Pepper

$26.14

0.03 (0.11%)

TAP

Molson Coors

$63.13

0.12 (0.19%)

KO

Coca-Cola

$49.45

0.25 (0.51%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 18

    Dec

  • 18

    Dec

  • 15

    Feb

  • 03

    Mar

VRTX

Vertex

$171.99

-3.56 (-2.03%)

12:20
12/13/18
12/13
12:20
12/13/18
12:20
Options
Sudden burst of activity in Vertex Pharma weekly calls »

Sudden burst of activity…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GE

General Electric

$7.31

0.59 (8.78%)

, AAPL

Apple

$170.93

1.84 (1.09%)

12:20
12/13/18
12/13
12:20
12/13/18
12:20
On The Fly
Fly Intel: Wall Street's top stories at midday »

Stocks have been…

GE

General Electric

$7.31

0.59 (8.78%)

AAPL

Apple

$170.93

1.84 (1.09%)

TSLA

Tesla

$371.13

4.37 (1.19%)

QD

Qudian

$6.47

1.21 (23.00%)

CIEN

Ciena

$34.64

2.505 (7.80%)

LLNW

Limelight Networks

$2.39

-0.81 (-25.31%)

TLRD

Tailored Brands

$14.13

-6.03 (-29.91%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 13

    Dec

ISRG

Intuitive Surgical

$511.49

-4.22 (-0.82%)

12:19
12/13/18
12/13
12:19
12/13/18
12:19
Recommendations
Intuitive Surgical analyst commentary  »

Piper still sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GH

Guardant Health

$41.25

-1.16 (-2.74%)

, AZN

AstraZeneca

$39.11

0.2 (0.51%)

12:17
12/13/18
12/13
12:17
12/13/18
12:17
Hot Stocks
Guardant Health, AstraZeneca partner to develop companion diagnostics tests »

Guardant Health (GH)…

GH

Guardant Health

$41.25

-1.16 (-2.74%)

AZN

AstraZeneca

$39.11

0.2 (0.51%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

12:17
12/13/18
12/13
12:17
12/13/18
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

12:16
12/13/18
12/13
12:16
12/13/18
12:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SFIX

Stitch Fix

$21.09

-1.23 (-5.51%)

12:15
12/13/18
12/13
12:15
12/13/18
12:15
Options
Stitch Fix put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SFTBF

SoftBank

$0.00

(0.00%)

, GS

Goldman Sachs

$176.57

-0.18 (-0.10%)

12:14
12/13/18
12/13
12:14
12/13/18
12:14
Hot Stocks
SoftBank Vision Fund leads $400M funding round in bio startup Zymergen »

Molecular manufacturing…

SFTBF

SoftBank

$0.00

(0.00%)

GS

Goldman Sachs

$176.57

-0.18 (-0.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BID

Sotheby's

$37.04

-0.06 (-0.16%)

12:12
12/13/18
12/13
12:12
12/13/18
12:12
Hot Stocks
Sotheby's Asia 2018 aggregate auction sales $985M, 'leads' Asia for last 3 years »

"2018 has been the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COHR

Coherent

$115.83

-1.93 (-1.64%)

12:10
12/13/18
12/13
12:10
12/13/18
12:10
Conference/Events
Coherent management to meet with Northcoast »

Field trip to company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Dec

XPO

XPO Logistics

$51.10

-9.15 (-15.19%)

, ECHO

Echo Global

$21.35

-0.41 (-1.88%)

12:05
12/13/18
12/13
12:05
12/13/18
12:05
Recommendations
XPO Logistics, Echo Global analyst commentary  »

XPO short report concerns…

XPO

XPO Logistics

$51.10

-9.15 (-15.19%)

ECHO

Echo Global

$21.35

-0.41 (-1.88%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CPRX

Catalyst Pharmaceuticals

$2.40

0.01 (0.42%)

12:05
12/13/18
12/13
12:05
12/13/18
12:05
Recommendations
Catalyst Pharmaceuticals analyst commentary  »

Catalyst pricing for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

SGAMY

Sega Sammy Holdings

$0.00

(0.00%)

, AMZN

Amazon.com

$1,659.51

-3.89 (-0.23%)

12:04
12/13/18
12/13
12:04
12/13/18
12:04
Periodicals
Sega rolls out classic Genesis games on Amazon Fire TV, Verge reports »

Sega (SGAMY) is bringing…

SGAMY

Sega Sammy Holdings

$0.00

(0.00%)

AMZN

Amazon.com

$1,659.51

-3.89 (-0.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Dec

  • 20

    Dec

MSI

Motorola Solutions

$129.01

-0.64 (-0.49%)

12:03
12/13/18
12/13
12:03
12/13/18
12:03
Conference/Events
Motorola Solutions management to meet with Northcoast »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 18

    Dec

  • 19

    Dec

GDI

Gardner Denver

$21.65

-0.2 (-0.92%)

12:01
12/13/18
12/13
12:01
12/13/18
12:01
Hot Stocks
Gardner Denver acquires MP Pumps for $58M in cash »

Gardner Denver Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NL

NL Industries

$3.92

(0.00%)

12:00
12/13/18
12/13
12:00
12/13/18
12:00
Hot Stocks
NL Industries falls -9.5% »

NL Industries is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XPO

XPO Logistics

$52.34

-7.91 (-13.13%)

12:00
12/13/18
12/13
12:00
12/13/18
12:00
Hot Stocks
XPO Logistics falls -13.1% »

XPO Logistics is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TLRD

Tailored Brands

$14.17

-5.99 (-29.71%)

12:00
12/13/18
12/13
12:00
12/13/18
12:00
Hot Stocks
Tailored Brands falls -29.6% »

Tailored Brands is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PPDF

PPDAI Group

$4.96

0.5 (11.21%)

12:00
12/13/18
12/13
12:00
12/13/18
12:00
Hot Stocks
PPDAI Group rises 11.2% »

PPDAI Group is up 11.2%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

M

Macy's

$30.56

-1.2825 (-4.03%)

12:00
12/13/18
12/13
12:00
12/13/18
12:00
Options
Call buyer in Macy's as shares shed 4% »

Call buyer in Macy's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.